Regarding NSCLC, anti-CTLA4 monotherapies are shadowed by the higher efficacy and tolerability of programmed death 1 (PD1) and programmed death ligand 1 (PD-L1) inhibitors. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.